GENB 8-K 2026-11-12

Generate Biomedicines, Inc. (GENB) 8-K dated 2026-11-12 — accession 0001193125-26-456921.

Generate Biomedicines, Inc. (GENB) common stock.

Generate Biomedicines, Inc. filed a 8-K on 2026-11-12. Accession 0001193125-26-456921.

This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.

Latest reported GENB revenue for 2026-06-30 was $6.3M. Net income was -$67.3M. Revenue was down 12.6% from 2026-03-31 to 2026-06-30. GENB currently screens at market cap $1.61B.

Not investment advice. The GENB SEC hub lists recent forms. The stock page is the research view.